在多发性髓瘤中,多模式抗原逃离到针对GPRC5D的T细胞参与者
Holly Lee1, Sungwoo Ahn1, Gerone A Gonzales2
1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.
Nature medicine
|January 15, 2026
概括
多发性骨髓瘤患者通过GPRC5D基因变异对T细胞诱导疗法产生抗性. 这些变化使得癌细胞能够逃避治疗,阻碍持久缓解,并需要新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 遗传学 遗传学 是一个
背景情况:
- 瘤内在的适应和耐药克隆阻碍了多发性骨髓瘤在T细胞向免疫疗法后的持久缓解.
- G蛋白结合受体,C类,第5组,D成员 (GPRC5D) 是多发性骨髓瘤中T细胞诱导剂 (TCE) 治疗的标.
研究的目的:
- 在多发性骨髓瘤中研究抗GPRC5DTCE治疗后瘤逃逸和抵抗的机制.
- 描述导致GPRC5D抗原丢失或功能障碍的基因组和表观基因组变化.
主要方法:
- 来自复发多发性骨髓瘤患者的克隆性血细胞的综合基因组,转录组和表观基因组分析.
- 对GPRC5D基因位置变化的分析,包括删除,单核酸变异和indels.
- 评估GPRC5D促进器/增强器区域的表观遗传沉默.
主要成果:
- 在反GPRC5DTCE治疗后,在68.4%的复发性多发性骨髓瘤病例中观察到GPRC5D的抗原漂移.
- 确定了GPRC5D变化的三个主要机制:双基删除,带有基突变的单基删除和表观遗传沉默.
- 突变影响了GPRC5D表位或蛋白质贩运,导致ER捕获;多个具有明显变化的子克隆同时出现.
- 不同的抗GPRC5DTCE以不同的方式准突变子克隆,突出了它们在克服抗性的独特作用.
结论:
- 瘤细胞进化出不同的基因组和表观基因组机制,以逃避多发性髓瘤中抗GPRC5D TCE疗法.
- GPRC5D变化的融合进化导致治疗耐药性.
- 了解这些抵抗机制对于制定实现持久缓解的策略至关重要.
更多相关视频
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
22.0K
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
11.8K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Diversity of Antigen Receptors
1.4K
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
1.4K
